CLIMB BIO, INC. Shareholders' Equity
CLIMB BIO, INC. (CLYM) had Shareholders' Equity of $239.55 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $239.55M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $148.09M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $160.47M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $177.00M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $239.55M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $148.09M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $160.47M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $177.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $185.76M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $193.38M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $211.88M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $218.78M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $222.28M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $106.38M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $107.60M 10-K · filed 2026-03-05 |
| 2023-09-30 | $109.74M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $112.50M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $116.86M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $128.72M 10-K · filed 2025-03-25 |
| 2022-09-30 | $134.36M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $142.24M 10-Q · filed 2023-11-14 |
| 2022-03-31 | $155.14M 10-Q · filed 2023-11-14 |
| 2021-12-31 | $167.20M 10-K · filed 2024-03-28 |
| 2021-09-30 | $176.66M 10-Q · filed 2022-11-14 |
| 2021-06-30 | -$50.84M 10-Q · filed 2022-11-14 |
| 2021-03-31 | -$43.18M 10-Q · filed 2022-11-14 |
| 2020-12-31 | -$24.98M 10-K · filed 2023-03-06 |
| 2020-09-30 | -$12.48M 10-Q · filed 2021-11-08 |
| 2020-06-30 | -$9.81M 10-Q · filed 2021-11-08 |
| 2020-03-31 | -$7.78M 10-Q · filed 2021-11-08 |
| 2019-12-31 | -$5.56M 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |